Amgen (AMGN) options expected to be active after reporting Repatha data
Tweet
Share
E-mail
Get Alerts AMGN Hot Sheet
Price: $385.65 +1.55%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.1%
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) March call option implied volatility is at 90, March weekly is at 41, April is at 26; compared to its 52-week range of 16 to 30 into releasing data for its 27,564-patient Repatha cardiovascular outcomes study,
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- On Holding AG (ONON) call put ratio 4.5 calls to 1 put with a focus on September 28 and 29 calls
- XPeng Inc. (XPEV) call put ratio 2.7 calls to 1 put with a focus on October 14 calls
- Boston Scientific (BSX) call put ratio 1.8 calls to 1 put with a focus on 25K contracts of December 75 calls
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
